All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The Hallmarks of Cancer are a core set of processes that are broadly deregulated in many types of cancer. Douglas Hanahan and Douglas Weinberg first introduced the concept, with six candidate hallmarks, in 2000. Since then, two additional hallmarks have been added. And the hallmarks have also been complemented by the description of enabling characteristics, which are prerequisites necessary for cells to acquire the hallmarks themselves.
Pfizer Inc.’s appetite for acquisitions shows no signs of abating as it announced this morning its plan to acquire biotech Seagen Inc. for a whopping $43 billion in a move that will double the size of its early stage oncology pipeline. Under the deal, unanimously approved by the boards of directors of both firms, Pfizer will pay Seagen $229 per share. Bothell, Wash.-based Seagen expects to amass $2.2 billion in revenue in 2023, representing 12% year-on-year-growth, royalties and collaboration and license agreements from its four, FDA-approved products for the treatment of solid tumors and hematologic malignancies, antibody-drug conjugate drugs Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin) and Tivdak (tisotumab vedotin), and tyrosin kinase inhibitor Tukysa (tucatinib).
Protein phosphatase 2A (PP2A) is a heterotrimer affecting approximately 60% of all serine/threonine phosphorylations. PP2A functions as a tumor suppressor when it is a trimer (PP2A-A-PP2Ac-B56) containing the B56 subunit. The B56 subunit is known to interact with up to 100 different proteins, but exactly how the PP2Aa/c-B56 complex is disrupted to initiate cancer has been poorly understood until now.
Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have developed urea compounds containing 2-heteroaromatic ring substitution that act as cyclin-dependent kinase 9 (CDK9) inhibitors.
A recent Moya Bio Ltd. patent describes fused azole and furan-based nucleoside analogues acting as ubiquitin-like modifier-activating enzyme 1 (UBA1; UBE1) inhibitors and thus reported to be potentially useful for the treatment of inflammation, cancer, parasitic infections and autoimmune diseases.
Researchers from Tonix Pharmaceuticals have presented preclinical data for mTNX-1700 (mTTF2-MSA), a novel recombinant fusion protein with an extended half-life, in anti-PD-1 treated colorectal cancer (CRC) models.
It has been previously demonstrated that necrosis is associated with metastatic dissemination of cancer cells; however, how necrosis promotes tumor dissemination is not understood. In a recent study, researchers from Fred Hutchinson Cancer Center and University of Washington aimed to investigate the correlation between tumor dissemination and the formation of large contiguous zones of necrosis within the tumor core.
Researchers from Memorial Sloan Kettering Cancer Center and affiliated organizations presented data from a study that aimed to investigate the immunomodulatory functions of lysine-specific demethylase 1 (LSD1) in regulating MHC-I antigen presentation pathway (APP) and resistance to immunotherapy in patients with small-cell lung cancer (SCLC).
CD73 is known to induce immune evasion in solid tumors by release of immune-suppressive adenosine in the tumor microenvironment. Researchers from Cidara Therapeutics Inc. have presented preclinical data on the CD73 inhibitor drug FC-conjugate CBO-212 for the potential treatment of solid tumors.
RSS
